These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35274403)

  • 41. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
    Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
    Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The eliminate hepatitis C (EC) experience study: baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia.
    Gunn J; O'Keefe D; Draper BL; Djordjevic F; Ryan K; Kerr P; Elsum I; Gold J; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana A
    BMJ Open; 2023 Jul; 13(7):e071665. PubMed ID: 37400235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.
    Hassan MRA; Chan HK; Nordin M; Yahya R; Sulaiman WRW; Merican SAA; Lah D; Sem X; Shilton S
    Harm Reduct J; 2023 Apr; 20(1):48. PubMed ID: 37046294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.
    Dawe J; Wilkinson AL; Asselin J; Carter A; Pedrana A; Traeger MW; Thomas AJ; Curtis M; Cooper M; Howell J; Doyle JS; Hellard ME; Stoové M;
    Int J Drug Policy; 2022 Jun; 104():103696. PubMed ID: 35490624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (the QuickStart Study): a cluster randomised cross-over trial protocol.
    Doyle JS; Heath K; Elsum I; Douglass C; Wade A; Kasza J; Allardice K; Von Bibra S; Chan K; Camesella B; Guzman R; Bryant M; Thompson AJ; Stoové MA; Snelling TL; Scott N; Spelman T; Anderson D; Richmond J; Howell J; Andric N; Dietze PM; Higgs P; Sacks-Davis R; Forbes AB; Hellard ME; Pedrana AE
    BMJ Open; 2024 Jul; 14(7):e083502. PubMed ID: 38960465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia.
    O'Keefe D; Jacka D; Douglass C; Gunn J; Stoove M; Crawford S; Bryant M; Higgs P; Dietze P; Hellard M
    J Viral Hepat; 2024 Mar; 31(3):151-155. PubMed ID: 38158743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Apparently, you can only be treated once": A qualitative study exploring perceptions of hepatitis C and access to treatment among people who inject drugs visiting a needle and syringe program.
    Fontaine G; Presseau J; Bruneau J; Patey AM; van Allen Z; Mortazhejri S; Høj SB; Hung JC; Grimshaw JM
    Int J Drug Policy; 2023 Nov; 121():104124. PubMed ID: 37451942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Point-of-care rapid testing for hepatitis C antibodies at New Zealand needle exchanges.
    Noller G; Bourke J
    N Z Med J; 2020 Nov; 133(1525):84-95. PubMed ID: 33223551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia.
    Gibbs D; Grebely J; Sutherland R; Larney S; Butler K; Dietze PM; Starr M; Peacock A
    Drug Alcohol Rev; 2021 Nov; 40(7):1349-1353. PubMed ID: 33759276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study.
    Martinez A; Cheng WH; Marx SE; Manthena S; Dylla DE; Wilson L; Thomas E
    Adv Ther; 2023 Aug; 40(8):3465-3477. PubMed ID: 37285080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015.
    Graham S; Maher L; Wand H; Doyle M; Iversen J
    Int J Drug Policy; 2017 Sep; 47():69-76. PubMed ID: 28735774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada.
    Broad J; Mason K; Guyton M; Lettner B; Matelski J; Powis J
    Int J Drug Policy; 2020 Jun; 80():102755. PubMed ID: 32416538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs.
    Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L
    Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.